Interpace Diagnostics Group, Inc. (75) | Note Agreements (6)
Recent Contracts
-
Subordinated Convertible Promissory Note to BroadOak Fund V, L.P., dated May 5, 2022
(Filed With SEC on May 10, 2022)
-
Amendment to Secured Promissory Note dated May 10, 2021 with Ampersand 2018 Limited Partnership
(Filed With SEC on August 11, 2021)
-
Amendment to Secured Promissory Note dated May 10, 2021 with1315 Capital II, L.P
(Filed With SEC on August 11, 2021)
-
Promissory Note entered into between the Company and Ampersand 2018 Limited Partnership, dated January 7, 2021
(Filed With SEC on May 11, 2021)
-
Promissory Note entered into between the Company and 1315 Capital II, L.P, dated January 7, 2021
(Filed With SEC on May 11, 2021)
-
Subordinated Seller Note of Interpace BioPharma, Inc., dated July 15, 2019, in favor of Cancer Genetics, Inc
(Filed With SEC on July 19, 2019)